News Briefs

RenalytixAI Developing AI-Enabled Clinical Diagnostic Products for Kidney Disease

RenalytixAI, a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, has raised $29 million to support the development and commercialization of two product categories for the early detection of kidney disease and accurate management of kidney transplant rejection. The launch of the first product, KidneyIntelX™, is planned for 2019; the launch will be conducted in collaboration with the Icahn ... Read More »

Specialist Nephrology Care Would Decrease US Health Care Costs

The RAND Corporation has released results from a recent analysis demonstrating that providing specialized medical care and coordination in patients with reduced kidney function prior to the need for dialysis treatment could save the US health care system more than $1 billion each year. According to a press release from the RAND corporation, approximately 60% of the savings would be ... Read More »

October 2018 News Briefs

Fresenius Awards $100,000 Grant to ANNA in Celebration of Nephrology Nurses Week   In recognition of the 50th anniversary year of the American Nephrology Nurses Association (ANNA) and in honor of Nephrology Nurses Week, September 9-15, Fresenius Medical Care North America has awarded ANNA a $100,000 grant. According to a press release from Fresenius Medical Care North America, the award ... Read More »

September 2018: News Briefs

Study 206 Begins Treatment of Patients with ALLN-177 for Hyperoxaluria Allena Pharmaceuticals, Inc., a late-stage biopharmaceutical company specializing in oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, has announced that the first patients have been enrolled and are being treated in a phase 2 basket study of ALLN-177. According to a press release, Study ... Read More »

July/August 2018: News Briefs

Lori Neal and Kevin Harris Named to NNCC Board of Commissioners Lori Neal, BSN, RN, CNN, and Kevin Harris have been appointed to the Board of Commissioners of the Nephrology Nursing Certification Commission (NNCC). In a June press release, NNCC announced that Ms. Neal and Mr. Harris will serve 2-year terms. Ms. Neal is a clinical support specialist for Fresenius ... Read More »

May/June 2018: News Briefs

Relypsa Research Grants Awarded to Three Institutions In a press release in April, Relypsa, a Vifor Pharma Group company, announced the presentation of three research grants to supplement institutional funding for nephrology and/or cardiology fellows who are researching hyperkalemia and other disorders. Alain Romero, PhD, PharmD, Relypsa vice president of medical and scientific affairs, said, “Our research grants aim to ... Read More »

April 2018: News Briefs

Two-Day Workshop Presents Data on Use of Earlier Markers of CKD Progression In mid-March, the National Kidney Foundation, in collaboration with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), concluded a scientific workshop to review the results of a major, multi-year meta-analysis designed to examine the “largest compilation of data ever collected on chronic kidney ... Read More »

November 2017: News Briefs

Cricket Names Danny Shapiro CBO Danny Shapiro has been named chief business officer of Cricket Health, a developer of technology-enabled care solutions for patients with chronic kidney disease and end-stage renal disease. Mr. Shapiro was most recently chief operating officer of Home Care Assistance and prior to that held the position of vice president at DaVita Kidney Care. In a ... Read More »

October 2017: News Briefs

LUTONIX® 035 DCB Granted FDA Approval In late August, the US FDA granted premarket approval to the LUTONIX® 035 drug coated balloon (DCB) PTA catheter. The LUTONIX 035 is now available in the United States. In a press release from C.R. Bard, Inc., the manufacturer of the catheter, Timothy M. Ring, chairman and chief executive officer, said, “This approval offers ... Read More »

September 2017: News Briefs

Veltassa Approved in European Union Market In late July, Relypsa, Inc., announced that Veltassa® (patiromer) received approval from the European Commission for its Marketing Authorization Application. Patiromer is indicated for the treatment of hyperkalemia (elevated levels of blood potassium). Veltassa is the brand name for patiromer in both the United States and Europe; it is approved for marketing in all ... Read More »